ScinoPharm Taiwan Ltd (台灣神隆), which makes active pharmaceutical ingredients (APIs), said it expects adverse market conditions to continue to affect its business this year.
The company’s core business of exporting generic drugs has been hit by falling prices as a series of mergers and acquisitions (M&A) raised the bargaining power of US-based drug distributors through joint procurements, it said.
The company also said it expects continued headwinds from a stronger New Taiwan dollar, after sales last year declined 6 percent due to exchange-rate fluctuations.
ScinoPharm on Friday reported that net income last year fell 36 percent annually to NT$422 million (US$14.4 million), with sales dipping 13 percent to NT$3.52 billion.
Earnings per share were NT$0.53, it said.
The company’s clients have trimmed their orders for Paclitaxel, a chemotherapy for ovarian and breast cancer, amid an inventory correction, while shipments of other major generic drugs were delayed due to the replacement and integration of product lines and factories in the wake of M&As among clients, ScinoPharm said.
However, the company said that manufacturing contracts for newly approved antibiotics Baxdela and Vibativ helped offset some of the lost sales in generic drugs.
ScinoPharm said that its partnership with Baxter International Inc has begun to bear fruit as it expands into the generic oncology injectibles market.
The partnership with the US-based Baxter enables the companies to jointly develop formulations while sharing the risks and profits, ScinoPharm said.
Royalties from its anticoagulant Fondaparinux last year increased significantly from a year earlier, it added.
As for the operations of its Changshu plant in China’s Jiangsu Province, ScinoPharm said that the increase in the plant’s revenue contribution has not been as fast as expected due to the rapidly changing environmental safety and health-related laws in China.
The company will continue with its strategy of integrating niche APIs and venturing into formulation, chief executive officer Fred Chen (陳勇發) said in a statement.
In terms of product selection, the company aims to prioritize the distribution of vertically integrated injectables, including small molecule injections and peptide APIs, Chen said.
Regarding the contract research and manufacturing business, the company is seeking new projects in targeted therapy and orphan drugs that have shorter development cycles, he said.
The domestic unit of the Chinese-owned, Dutch-headquartered chipmaker Nexperia BV will soon be able to produce semiconductors locally within China, according to two company sources. Nexperia is at the center of a global tug-of-war over critical semiconductor technology, with a Dutch court in February ordering a probe into alleged mismanagement at the company. The geopolitical tussle has disrupted supply chains, with some carmakers reportedly forced to cut production due to chip shortages. Local production would allow Nexperia’s domestic arm, Nexperia Semiconductors (China) Ltd (安世半導體中國), to bypass restrictions in place since October on the supply of silicon wafers — etched with tiny components to
Singapore-based ride-hailing and delivery giant Grab Holdings Ltd has applied for regulatory approval to acquire the Taiwan operations of Germany-based Delivery Hero SE's Foodpanda in a deal valued at about US$600 million. Grab submitted the filing to the Fair Trade Commission on Friday last week, with the transaction subject to regulatory review and approval, the company said in a statement yesterday. Its independent governance structure would help foster a healthy and competitive market in Taiwan if the deal is approved, Grab said. Grab, which is listed on the NASDAQ, said in the filing that US-based Uber Technologies Inc holds about 13 percent of
Taiwan is open to joining a global liquefied natural gas (LNG) program if one is created, but on the condition that countries provide delivery even in a scenario where there is a conflict with China, an energy department official said yesterday. While Taiwan’s priority is to have enough LNG at home, the nation is open to exploring potential strategic reserves in other countries such as Japan or South Korea, Energy Administration Deputy Director-General Chen Chung-hsien (陳崇憲) said. While the LNG market does not have a global reserve for emergencies like that of oil, the concept has been raised a few times —
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday received government approval to deploy its advanced 3-nanometer (3nm) process at its second fab currently under construction in Japan, the Ministry of Economic Affairs said in a news release. The ministry green-lit the plan for the facility in Kumamoto, which is scheduled to start installing equipment and come online in 2028 with a monthly production capacity of 15,000 12-inch wafers, the ministry said. The Department of Investment Review in June 2024 authorized a US$5.26 billion investment for the facility, slated to manufacture 6- to 12nm chips, significantly less advanced than 3nm process. At a meeting with
RSS